|
Novavax News is an EIN News Service for health professionals. Constantly updated news and information about health.
- BioWatch: HGS seeks OK for hepatitis C treatment 26 Nov 2009 10:12 GMT
... federal regulatory approval to market its new treatment for hepatitis C. The Rockville biotech is ... could total $507.5 million, HGS said. The drug is made by genetically fusing human albumin, ... applied for FDA marketing approval in May. Novavax has raised about $21 million in a ...
- Vaccine system remains antiquated 24 Nov 2009 06:06 GMT
... against using adjuvants because the Food and Drug Administration has not fully reviewed them. Officials worried ... process dependent on chickens would be vulnerable. Pharmaceutical companies, however, have had little incentive to ... it worked in children and was safe. Novavax of Rockville is testing a similar vaccine ...
- Stocks on the move: Consol, Dell, Leap, LogMeIn, Merck, Novavax 20 Nov 2009 18:12 GMT
... Average, adding 2.5 percent to $36.20. The drugmaker said the Committee for Medicinal Products for ... Agency recommended approval of Elonva as a treatment in controlled ovarian stimulation in combination with ... participating in an assisted reproductive technology program. Novavax Inc. (NVAX US) fell 11 percent to ...
- News and FDA Updates for Genta (OTC:GETA), POZEN (NASDAQ:POZN), Novavax (Nasdaq:NVAX) 21 Nov 2009 18:26 GMT
... FDA Updates for Genta (OTC:GETA), POZEN (NASDAQ:POZN), Novavax (Nasdaq:NVAX) BioMedReports.Com, the news portal which covers ... to the public of $3.30 per share. Biotech investors interested in seeing more details about ... flows, contract awards, FDA announcements, trial and drug approvals, and company stability. Forward-looking statements are made ...
- BiomedReports: News and FDA Updates for Genta (OTC:GETA), POZEN (NASDAQ:POZN), Novavax (Nasdaq:NVAX) 23 Nov 2009 12:34 GMT
... risk for associated gastric ulcers. On 11/20/09, Novavax, Inc. (Nasdaq:NVAX) announced it has priced an ... to the public of $3.30 per share. Biotech investors interested in seeing more details about ... flows, contract awards, FDA announcements, trial and drug approvals, and company stability. Forward-looking statements are made ...
- Drug developer Novavax to offer 6.8 million shares of common stock at $3.30 each; stock falls 20 Nov 2009 16:25 GMT
... ROCKVILLE, Md. (AP) - Biotech drug developer Novavax Inc. said Friday it plans to offer 6.8 million of its shares in an ...
- Novavax plans offering of 6.8M shares; stock falls 20 Nov 2009 16:25 GMT
... ROCKVILLE, Md. (AP) - Biotech drug developer Novavax Inc. said Friday it plans to offer 6.8 million of its shares in an ...
- Novavax Prices Public Offering of Common Stock 20 Nov 2009 14:50 GMT
... Novavax Prices Public Offering of Common Stock ROCKVILLE, Md., ... be used for preclinical studies and clinical trials of our VLP-based vaccines, internal research and ... such state or jurisdiction. is a clinical-stage biotechnology company, creating novel vaccines to address a ...
- Novavax to raise $21M 20 Nov 2009 16:05 GMT
... , moving closer to commercializing its flu vaccines, will raise $21 million in a secondary ... 44 cents, to $3.33 in Friday trading. Novavax shares have more than doubled in the ... year. The company has already started clinical trials with 4,000 patients in Mexico, where it ...
- PiperJaffray, Lazard Capital Markets to run Novavax share offering 23 Nov 2009 08:16 GMT
... 20 November 2009 - US clinical-stage biotechnology company Novavax (NASDAQ: NVAX) has picked US investment banking firms ... will use for preclinical studies and clinical trials, R&D, working capital and other general corporate ...
- Novavax Announces Public Offering of Common Stock 20 Nov 2009 13:11 GMT
... Novavax Announces Public Offering of Common Stock ROCKVILLE, Md., ... such state or jurisdiction. is a clinical-stage biotechnology company, creating novel vaccines to address a broad range of infectious ...
- Novavax Announces Public Offering of Common Stock 20 Nov 2009 13:45 GMT
... ROCKVILLE, Md., Nov. 20 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it intends ... such state or jurisdiction. is a clinical-stage biotechnology company, creating novel vaccines to address a broad range of infectious ...
- Novavax Plans Offering Of 6.8M Shares; Stock Falls 20 Nov 2009 16:19 GMT
... $3.36 in morning trading. The offering, which Novavax expects to close on or about Nov. ... be used for preclinical studies and clinical trials of vaccines the company is developing, as well as ...
- Novavax Down 38.8% Since SmarTrend's Sell Recommendation 23 Nov 2009 21:39 GMT
... pattern recognition system, called a Downtrend for Novavax (NASDAQ:NVAX) on September 17, 2009 at $5.00. ... to www.mysmartrend.com now for a FREE two-week trial. SmarTrend analyzes over 5,000 securities simultaneously throughout the ...
- Novavax Announces Public Offering of Common Stock (PRN) 20 Nov 2009 13:16 GMT
... is a clinical-stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary ...
Powered by 
These stories are not published by IPD Group, Inc. and these links will take you to other websites. Some of these websites require their own registration to read their stories.
<<< Please read the disclaimer for more details.>>> | |
Healthcare Industry Today
|
a digital news provider
nytimes.com:
reuters.com:
wsj.com:
wsj.com:
msnbc.msn.com:
bbc.co.uk: